首页> 外国专利> METHOD FOR ASSESSING THE RISK OF PROGRESSING INTRAEPITITAL CERVICAL NEOPLASIA AND THE DEVELOPMENT OF Cervical Cancer ON THE BASIS OF DETERMINING HUMAN GENE mRNA LEVELS

METHOD FOR ASSESSING THE RISK OF PROGRESSING INTRAEPITITAL CERVICAL NEOPLASIA AND THE DEVELOPMENT OF Cervical Cancer ON THE BASIS OF DETERMINING HUMAN GENE mRNA LEVELS

机译:基于确定人类基因mRNA水平的进展性脑膜内宫颈病变和宫颈癌发展的评估方法

摘要

A method for assessing the risk of progression of intraepithelial cervical neoplasia and the development of cervical cancer based on the determination of human gene mRNA levels, characterized in that the mRNA levels of human genes MKI67, CDKN2A are measured or any other markers of cell cycle proliferation and regulation are used, changes in the expression level of which with the progression of intraepithelial cervical neoplasia and the development of cervical cancer correlates with the expression level of MKI67, CDKN2A, in particular CCNB1, BIRC5, AURKA; BCL2 or use any other markers of apoptosis, the change in the expression level of which with the progression of intraepithelial cervical neoplasia and the development of cervical cancer correlates with the expression level of BCL2, in particular BAX, BAG1, NDRG1; PGR or use any other markers of the receptor apparatus of cells, the change in the expression level of which with the progression of intraepithelial cervical neoplasia and the development of cervical cancer correlates with the expression level of PGR, in particular ESR1, CD68, in the samples from the lesion sites and the values of mRNA obtained during the reaction are substituted into the formula, where p is the risk of neoplastic transformation; z is the value of the regression function, is determined by the formula z = b1 * X1 + b2 * X2 + ... + bn * Xn + a, where X1 ... Xn is the level of expression of the gene mRNA or the index of the ratio of the level of ex gene pressures; b1 ... bn - regression coefficients; a is a constant; in this case, if the p value is less than or equal to the threshold value (p≤cut-off), conclude that there is no risk of malignancy; if the value p cut-off, make a conclusion about the progression of the disease and the high risk of neoplastic transformation; the threshold value is determined on the basis of experimental data using ROC analysis.
机译:一种基于确定人类基因mRNA水平的评估上皮内宫颈瘤形成和宫颈癌发展风险的方法,其特征在于测量人类基因MKI67,CDKN2A的mRNA水平或细胞周期增殖的任何其他标志物使用和调节,其表达水平的变化与上皮内宫颈瘤的发展和子宫颈癌的发展与MKI67,CDKN2A,特别是CCNB1,BIRC5,AURKA的表达水平相关; BCL2或使用任何其他凋亡标记物,其表达水平的变化与上皮内宫颈赘生物的进展和宫颈癌的发展与BCL2的表达水平相关,尤其是BAX,BAG1,NDRG1; PGR或使用细胞受体装置的任何其他标志物,其表达水平的变化与上皮内宫颈癌的发展和宫颈癌的发生有关,与PGR,特别是ESR1,CD68的表达水平相关。将病变部位的样品和在反应过程中获得的mRNA的值代入公式,其中p为肿瘤转化的风险; z是回归函数的值,由公式z = b1 * X1 + b2 * X2 + ... + bn * Xn + a决定,其中X1 ... Xn是基因mRNA的表达水平或前基因压力水平之比的指数; b1 ... bn-回归系数; a是一个常数;在这种情况下,如果p值小于或等于阈值(p≤截止值),则得出没有恶性风险的结论;如果p>截断值,则可以推断出疾病的进展和肿瘤转化的高风险;阈值是基于使用ROC分析的实验数据确定的。

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号